Elsevier

The Lancet

Volume 339, Issue 8792, 29 February 1992, Pages 507-510
The Lancet

ORIGINAL ARTICLES
Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age

https://doi.org/10.1016/0140-6736(92)90336-2Get rights and content

Abstract

In the UK an accelerated schedule for immunisation against diphtheria, tetanus, and pertussis (injections at 2, 3, and 4 months of age) was introduced in 1990 to replace the more widely spaced schedule of 3, 5, and 9 months. There is concern, however, that the new schedule may be less immunogenic and therefore less protective than the old schedule. We have measured serum concentrations of antibodies against diphtheria, pertussis, and tetanus in infants immunised according to the two regimens. Both schedules resulted in protective concentrations of antibody against tetanus and diphtheria and in satisfactory antibody responses to three pertussis antigens (filamentous haemagglutinin, pertussis toxin, fimbriae). However, immunisation by the old schedule led to significantly higher antibody concentrations against both diphtheria and tetanus than did immunisation by the new schedule (p < 0·01). In infants immunised with the new schedule, postimmunisation antibody concentrations against tetanus toxoid and against two pertussis antigens (pertussis toxin and fimbriae) were significantly lower in infants in whom pre-immunisation (maternally derived) antibody concentrations were high (p < 0·02). The findings suggest that with an accelerated immunisation schedule maternal antibodies can have an inhibitory effect on the responses to immunisation against tetanus and pertussis.

References (20)

There are more references available in the full text version of this article.

Cited by (104)

  • Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis

    2021, Vaccine
    Citation Excerpt :

    A previous study by Simondon et al showed that infants immunized with a 2-, 4-, 6-month primary immunization schedule had a significantly higher immune response to pertussis (measured by neutralization assay) than infants immunized with a 2-, 3-, 4-month schedule [40]. Similarly, the work by Booy et al showed that immunization with 3-, 5-, 9-months schedule was associated with significantly higher antibody levels against diphtheria and tetanus compared with immunization at 2-, 3-, 4-months [22]. The underlying mechanism for the association between longer intervals between vaccine doses and higher antibody levels requires further investigation.

  • Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6–8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study

    2019, Vaccine
    Citation Excerpt :

    A literature search on the subject was conducted and it was found that earlier studies also observed low antibody titre against the tetanus component. In a study published in1992 (on antibody response in infants after one month of vaccination with 3 doses of DTP and Hib conjugate vaccine, concurrently but at separate sites, at the age of 3, 5 and 9 months), Robert Booy et al. reported significantly lower antibody against tetanus toxoid and pertussis antigens in infants in whom pre-immunization (maternally derived) antibody concentrations were high [21]. Adarsh Eregowda et al. reported (in 2013) highly significant rise in antibody titre for all components except tetanus, after one month of vaccination with 3 doses (administered at 6, 10 and 14 weeks of age) of a pentavalent DTwP–HepB–Hib vaccine in Indian infants, which they attributed to presence of maternal antibodies [22].

  • Pertussis and influenza immunisation during pregnancy: a landscape review

    2017, The Lancet Infectious Diseases
    Citation Excerpt :

    In a South African study44 maternal inactivated influenza vaccine administration was 48·8% (11·6–70·4) efficacious for the prevention of influenza in infants. Several studies done in the 1990s and recent data suggest that high maternally derived antibody titres (pre-existing or boosted by Tdap immunisation before or during pregnancy) can have a suppressive effect on infant responses to primary immunisation against pertussis, although the clinical significance of this observation has not been evaluated (table 2).13,18–20,60,85–90 Interference with active immunisation against pertussis was not only affected by the concentrations of maternal antibodies, but also by the type of pertussis vaccine administered to the infant.

  • Diphtheria Toxoid

    2017, Plotkin's Vaccines
  • Tetanus Toxoid

    2017, Plotkin's Vaccines
View all citing articles on Scopus
View full text